Avery Sonnenberg

Talus Bio is making the regulome visible and druggable. We are building the first platform to map, model, and ultimately write the regulome, unlocking thousands of previously undruggable targets, including transcription factors that drive cancer, autoimmunity, and neurodegeneration. Our platform measures the regulome directly in living human cells, generating functional datasets at scale for the first time. These data fuel AI models that learn the logic of genome regulation and predict how to modulate it with precision.

Inimmue is a new biotechnology company founded by pharmaceutical industry veterans focused on developing next generation immunotherapeutics.

FYR is revolutionizing the ability to dynamically observe disease and treatment response to produce better biomarkers, trials, drugs and outcomes. FYR’s EV-Omics (EVO) platform leverages its proprietary technology, SPARCs, to enrich for extracellular vesicles from diseased cells and enable the deep assessment of proteins and nucleic acids from a simple blood draw. Utilizing AI-enabled multiomic insights, EVO unravels the complexity of disease mechanisms, thereby informing potential diagnostic and treatment options. The unparalleled view provided by FYR’s multiomic approach can transform personalized patient care, from screening through therapy selection and monitoring. For more, visit fyr.bio.

Talus Bio is making the regulome visible and druggable. We are building the first platform to map, model, and ultimately write the regulome, unlocking thousands of previously undruggable targets, including transcription factors that drive cancer, autoimmunity, and neurodegeneration. Our platform measures the regulome directly in living human cells, generating functional datasets at scale for the first time. These data fuel AI models that learn the logic of genome regulation and predict how to modulate it with precision.

Inimmue is a new biotechnology company founded by pharmaceutical industry veterans focused on developing next generation immunotherapeutics.

FYR is revolutionizing the ability to dynamically observe disease and treatment response to produce better biomarkers, trials, drugs and outcomes. FYR’s EV-Omics (EVO) platform leverages its proprietary technology, SPARCs, to enrich for extracellular vesicles from diseased cells and enable the deep assessment of proteins and nucleic acids from a simple blood draw. Utilizing AI-enabled multiomic insights, EVO unravels the complexity of disease mechanisms, thereby informing potential diagnostic and treatment options. The unparalleled view provided by FYR’s multiomic approach can transform personalized patient care, from screening through therapy selection and monitoring. For more, visit fyr.bio.

Two Bear Capital is a venture capital firm that invests in entrepreneurs who have breakthrough ideas in life sciences and technology. Two Bear Capital’s vision is to build an ecosystem of support, economic opportunity and innovation that brings the most meaningful ideas to market in the form of enduring high-impact businesses that benefit society as a whole, while delivering for investors. The firm primarily focuses on early, founder-led companies with disruptive innovations in biotechnology, bioinformatics, healthcare IT, machine learning and AI, and information security. Two Bear Capital has offices in Menlo Park, San Diego, Boston, and New York, with its home base in Whitefish, Montana. It was founded in 2019 by Mike Goguen.

BD is one of the worlds largest pure-play medical technology companies with a Purpose of advancing the world of health™ by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com. See community guidelines here: https://tinyurl.com/yunjmzkx.